Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range
Executive Summary
PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
You may also be interested in...
Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity
Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.
Global Device Approvals Snapshot: April 9-15, 2019
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Qiagen's therascreen FGFR RGQ RT-PCR companion diagnostic for Janssen's new drug to treat specific types of urothelial cancer and Intact Vascular's Tack device to treat dissections of the above-the-knee peripheral arteries following angioplasty.
Gelesis100 Reduces Insulin-Resistance in GLOW Obesity Trial
Data from the pivotal GLOW trial presented at the Endocrine Society's annual meeting show that Gelesis' Gelesis100 non-systemic, superabsorbent hydrogel significantly reduces insulin-resistance compared to placebo in overweight and obese patients.